Renovaro secures U.S. patent for AI-driven drug discovery, diagnostics platform

Renovaro announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions”. This patent strengthens Renovaro’s AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources-such as genomics, electronic health records, imaging, and clinical trial data-into a standardized framework for predictive modeling. The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale.